BPC 157, a synthetic peptide, is linked in laboratory and animal studies to helping maintain the gut lining's barrier function when exposed to NSAIDs, which may reduce damage caused by these drugs.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of randomized controlled trials in humans would determine whether BPC 157 administration consistently reduces NSAID-induced intestinal permeability and clinical gastrointestinal injury compared to placebo or standard care.
A systematic review and meta-analysis of all published randomized, double-blind, placebo-controlled trials in adults (18–75 years) taking chronic NSAIDs (e.g., ibuprofen 400–800 mg/day or naproxen 500 mg/day) for at least 4 weeks, with BPC 157 administered orally or subcutaneously at 10 µg/kg/day, measuring primary outcomes: fecal calprotectin, serum zonulin, and endoscopic evidence of small intestinal mucosal injury via capsule endoscopy, with secondary outcomes including gastrointestinal symptom scores and adverse events.
A well-conducted RCT would determine whether BPC 157 causally reduces NSAID-induced intestinal permeability and mucosal injury in humans compared to placebo.
A double-blind, placebo-controlled trial of 120 healthy adults aged 25–55 taking daily naproxen 500 mg for 14 days, randomized to receive oral BPC 157 (10 µg/kg twice daily) or placebo, with primary outcome: change in intestinal permeability measured by lactulose/mannitol urinary excretion ratio, secondary outcomes: endoscopic small bowel injury score via capsule endoscopy, serum zonulin, and fecal calprotectin levels.
A prospective cohort study would determine whether individuals taking BPC 157 while on NSAIDs have lower rates of clinically significant gastrointestinal injury over time compared to those not taking it.
A prospective cohort study following 500 patients with chronic inflammatory conditions (e.g., rheumatoid arthritis) requiring long-term NSAID use, stratified by BPC 157 use (yes/no), tracking incidence of overt GI bleeding, anemia, and endoscopic mucosal lesions over 12 months, adjusting for age, NSAID dose, and concomitant PPI use.
A case-control study would assess whether prior exposure to BPC 157 is less common among patients who develop NSAID-induced intestinal ulcers compared to matched controls without ulcers.
A case-control study comparing 100 patients with confirmed NSAID-induced small bowel ulcers (via capsule endoscopy) to 200 matched controls without ulcers, retrospectively assessing prior use of BPC 157 (dose, duration, route) and adjusting for NSAID type, duration, and comorbidities.
A cross-sectional study would identify whether individuals currently using BPC 157 report fewer gastrointestinal symptoms while on NSAIDs compared to non-users at a single time point.
A cross-sectional survey of 1000 adults taking NSAIDs for at least 3 months, assessing current BPC 157 use (yes/no, dose, duration) and self-reported GI symptoms (e.g., abdominal pain, bloating, diarrhea) using validated questionnaires, with no follow-up or objective biomarkers.